MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of healthcare and life science industry veteran Jovan Willford to its Board of Directors.
“We are excited to welcome Jovan to our Board of Directors. He brings a deep understanding of our business and a proven track record of transforming healthcare technology and advanced analytics companies,” said Richard Daly, CEO at DNAnexus. “Over the past year, we have made significant strides as an organization with the additions to the team and $200 million financing. This year, we will look to rapidly scale our operations and further accelerate the global adoption of our industry-leading platform.”
Mr. Willford brings more than 20 years of industry experience in healthcare technology-enabled services, software, and data. He is currently a Senior Advisor for TPG, a leading global alternative asset manager with $135 billion in assets under management. Previously, he served as CEO and as a board director at Healthgrades / Mercury Healthcare, where he oversaw the successful sale of two stand-alone businesses. Prior to that, Mr. Willford spent nearly a decade in senior leadership roles at IQVIA, a Fortune 300 company providing advanced analytics, technology solutions, and clinical research services across the life sciences industry. Earlier in his career, he served as a consultant working at the intersection of payers, providers, and life sciences. Mr. Willford holds an MBA from the University of Northwestern’s Kellogg School of Management and an undergraduate degree from the University of Notre Dame.
“DNAnexus sits at the forefront of the next era in healthcare data, powering the foundational infrastructure essential to drive innovations in diagnostics, medical devices, and pharmaceuticals,” said Willford. “I’m looking forward to working with the team to help scale its global network and to empower more researchers with the ability to translate massive multi-omic datasets into tangible insights that ultimately improve patient care.”
Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. The platform provides a comprehensive cloud environment that was designed to meet the most rigorous standards for quality, security, privacy, and safety.
About DNAnexus
DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 65 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.
